Multiple Myeloma
Conditions
Keywords
Patient Experience, Treatment Preference, Qualitative Study, Patient Interviews
Brief summary
This is a qualitative (interview) study to explore the experiences of people receiving treatment for MM and to understand what matters most to participants when making treatment decisions.
Detailed description
People can receive many lines of treatment for multiple myeloma. The investigators would like to understand more about the experiences of people being treated for multiple myeloma including what matters most to participants when considering treatment options, how participants experiences have differed with different treatments and if participants have any treatment preferences. Patients at The Christie who have received five or more lines of treatment for Multiple Myeloma will be eligible to take part in this study. Participants will be asked to take part in an interview which should take approximately 30 minutes to an hour. During the interview, participants will be asked questions regarding their experiences and preference for treatment. Interviews will be conducted either in person or over the phone depending on patient preference. The interviews will be recorded by the research team using a Dictaphone and transcribed by an external transcription service called 1st Class Secretarial. The transcripts of all participant interviews will be reviewed by members of the research team and experiences will be identified and described.
Interventions
OTHERPatient Interview
Participants will be asked to take part in a 30-60 minute interview to understand their treatment experiences and preferences.
Sponsors
The Christie NHS Foundation Trust
CellCentric Ltd.
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Participants with confirmed MM (per standard disease specific diagnostic criteria) 2. Participants must have received ≥ 5 lines of treatment for MM and fit into one of the below treatment categories: 1. Subset 1- Participants must have received an oral anti-cancer therapy and a bi-specific antibody treatment. 2. Subset 2- Participants must have received an oral anti-cancer therapy and if they have not had a bi-specific antibody treatment, they must have received at least one IV therapy. 3. Aged 18 years of age or over 4. Able to provide informed consent 5. Able to communicate in English
Exclusion criteria
1. Aged under 18 2. Unable to understand and communicate in the English language 3. Unable to provide written informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patient Experience and Preference | 30-60 minutes | The interview will explore the experiences of people receiving treatment for multiple myeloma and understand what matters most to them when making treatment decisions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Treatment and Preference Differences | 30-60 minutes | The interview will explore how experiences have differed across different lines of treatment and determine if people with multiple myeloma have any preferences for particular treatments. |
Countries
United Kingdom
Contacts
PRINCIPAL_INVESTIGATORSally Taylor, PhD
The Christie NHS Foundation Trust
Outcome results
None listed